Latest news for Hemostemix (OTC:HMTXF) Stock

Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.

Biotech

Cannabis

News

Penny Stocks

Emerging Markets

Markets

General

ACOGF

BABYF

EMMA

HMTXF

JNHMF

MCURF

RDHL

RLFTF

RSLS

RSPI

SLRX

VNRX

TSXV:ACOG

TSXV:HEM

TSXV:BABY

Photo by Chris Montgomery on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday

Hemostemix Inc

Buybacks

STNE

Reported Earlier, StoneCo Announces R$2B Repurchase Plan, Replacing Previous Buyback Program

BENF

Reported Earlier, Beneficient Highlights TEFFI Impact: $126M Equity Gain, $3M Grants, And $5B Financing Capacity

Huawei Technologies Co. is reportedly set to release its most advanced domestically made chip in the Mate 70 series, amid ongoing U.S. sanctions.
What Happened: The new chip will power select models in Huawei's Mate 70 lineup, which is expected to launch next week, <a href="https://www.wsj.com/tech/huaweis-chip-advances-threaten-apple-in-china-165a1e9e?mod=tech_lead_story">reported</a> the Wall Street Journal, citing people familiar with the matter.
The launch comes as Huawei continues to increase its market share in China, where it has seen a rise in consumer demand.
In the third quarter of this year, Huawei's market share in China grew to 15.3% from 8.6% last year, positioning it as a significant competitor to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in the high-end smartphone market.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/41017367/huawei-riding-high-on-trifold-success-launches-revolutionary-laptop-powered-by-homegrown-chips-softw">Huawei, Riding High On Trifold Success, Launches Revolutionary Laptop Powered By Homegrown Chips, Software — China Ready To Break Free From US Tech Dependence?</a>
The new chips, produced by Semiconductor Manufacturing International Corporation or SMIC, leverage advanced technologies to improve performance and power efficiency, allowing Huawei to compete more effectively with Apple's offerings.
&#8220;The Mate 70 will continue to put more pressure on Apple in China,&#8221; said IDC vice president Bryan Ma, according to the report.
Although Huawei's chips still lag behind Apple's in terms of power efficiency, he noted that the difference may not be significant as long as users can get through the day without worrying about charging, the report noted.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: This development coincides with an earlier report that suggested Huawei plans to begin <a href="https://www.benzinga.com/news/24/11/42105518/huawei-to-reportedly-take-on-nvidia-with-mass-production-of-new-ai-chips-by-2025-amid-us-restrictions">mass production of its new AI chip</a>, the Ascend 910C, in early 2025, despite facing major challenges from U.S. trade restrictions.
In May earlier this year, the Joe Biden administration <a href="https://www.benzinga.com/markets/asia/24/05/38682654/biden-administration-tightens-grip-on-chinas-huawei-revokes-key-export-licenses-from-us-chipmakers">canceled export licenses</a> for leading U.S. semiconductor companies such as Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), blocking them from providing essential chips to Huawei.
During the same month, a report from Counterpoint Research suggested that <a href="https://www.benzinga.com/news/24/05/39107001/after-apple-huawei-takes-on-samsung-in-race-to-become-worlds-top-foldable-phone-maker-report">Huawei surpassed</a> Samsung Electronics Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) in global foldable smartphone shipments for the first quarter of 2024.
Last month, U.S. lawmakers called on the Department of Commerce to take stronger measures against Huawei&#8217;s reported efforts to evade sanctions by using a <a href="https://www.benzinga.com/markets/asia/24/10/41368844/us-lawmakers-demand-tougher-action-on-huaweis-secretive-chip-network">covert network of semiconductor facilities</a>.
Price Action: At the time of writing, Apple shares increased by 0.02% to $228.56 in after-hours trading, following a 0.21% decline to $228.52 during Thursday's regular session, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40953906/huaweis-2-800-tri-fold-mate-xt-sparks-frustration-as-limited-stock-fails-to-meet-demand">Huawei&#8217;s $2,800 Tri-Fold Mate XT Sparks Frustration As Limited Stock Fails To Meet Demand</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Global

Tech

Media

AAPL

INTC

QCOM

SSNLF

Huawei To Launch Mate 70 Smartphone With Advanced Homegrown Chip, Challenging Apple In China Amid US Sanctions: Report

Abacus intends to use net proceeds of the primary portion of the offering for its operations, including the purchase of life settlement policies, to support its overall business strategy, for working capital purposes, and for general corporate purposes, which may include funding previously announced and future acquisitions and repayment and refinancing of its indebtedness. Abacus will receive no proceeds from the secondary portion of the offering.

Reported Earlier, Abacus Life Prices $100M Public Offering Of 12.5M Common Shares At $8 Per Share

President-elect Donald Trump&#8216;s <a href="https://www.msn.com/en-us/money/news/trumps-doge-with-musk-at-the-helm-riddled-with-conflicts-of-interest-says-clinton-era-official-robert-reich/ar-AA1u3Joj">appointed DOGE</a> or the Department of Government Efficiency could potentially save $50–100 billion annually, according to Congressional Budget Office (CBO) analyses, said Mario Georgiou, CFA and executive director, head of investments at InCred Global Wealth U.K.
What Happened: Georgiou said that DOGE &#8220;tasked with cutting wasteful spending, could play a role in improving fiscal discipline, but the scale of potential savings is expected to be modest.&#8221;
The U.S. federal budget deficit could reach $1.7 trillion in 2024, entailing mandatory spending on Social Security and Medicare, which accounts for over 60% of expenditures, Georgiou said. &#8220;Even if the DOGE achieves its objectives, potential savings are estimated at $50–100 billion annually, according to Congressional Budget Office analyses, which would have only a marginal impact compared to total federal outlays of approximately $6.7 trillion in 2024,&#8221; he added.
However, Tesla Inc. and SpaceX CEO Elon Musk <a href="https://www.benzinga.com/news/24/11/42069803/elon-musks-doge-job-applications-require-x-premium-subscription">who will co-lead DOGE</a> with Republican politician Vivek Ramaswamy had called for &#8220;at least $2 trillion&#8221; in budget cuts last month while speaking at a rally in New York.
On Wednesday, Musk and Ramaswamy outlined their vision for DOGE, &#8220;The two of us will advise DOGE at every step to pursue three major kinds of reform: regulatory rescissions, administrative reductions, and cost savings,&#8221; the duo wrote in a <a href="https://www.wsj.com/opinion/musk-and-ramaswamy-the-doge-plan-to-reform-government-supreme-court-guidance-end-executive-power-grab-fa51c020">WSJ</a> opinion piece on Nov. 20.
Why It Matters: In their opinion piece, the duo said &#8220;DOGE will help end federal overspending by aiming $500 billion-plus in annual federal expenditures that are unauthorized by Congress or being used in ways that Congress never intended.&#8221;
Musk and Ramaswamy aimed a few expenditure programs along with $300 million provided to the other &#8220;progressive groups.&#8221; They mentioned $535 million allotted to the Corporation for Public Broadcasting and $1.5 billion in grants to Planned Parenthood annually.
Discretionary spending—where most inefficiencies and &#8220;waste&#8221; are typically identified, &#8220;constitutes a smaller portion of the budget and offers limited opportunities for impactful cuts​​,&#8221; Georgiou added.
Musk and Ramaswamy highlighted that several federal contracts have gone unexamined for years. They suggested that a temporary suspension of payments would facilitate comprehensive audits, resulting in substantial cost savings.
&#8220;The Pentagon recently failed its seventh consecutive audit, suggesting that the agency's leadership has little idea how its annual budget of more than $800 billion is spent.&#8221;
Also read: <a href="https://www.benzinga.com/markets/equities/24/11/42105450/elon-musk-says-amazon-founder-jeff-bezos-urged-tesla-spacex-investors-to-dump-stakes-predicting-trumps-loss">Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump&#8217;s Loss</a>
&#8220;We are focused on delivering cost savings for taxpayers,&#8221; the duo said in their piece.
Musk and Ramaswamy swiftly defended their stance on cutting the budgets of a few entitlement programs. &#8220;Critics claim that we can't meaningfully close the federal deficit without aiming for entitlement programs like Medicare and Medicaid, which require Congress to shrink. But this deflects attention from the sheer magnitude of waste, fraud, and abuse that nearly all taxpayers wish to end,&#8221; they added.
Read next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42130859/as-trump-backs-drill-baby-drill-his-doge-co-lead-elon-musk-believes-all-energy-generation-will-be-solar-heres-what-ubs-recommends-after-election-dip">As Trump Backs &#8216;Drill Baby, Drill,&#8217; His DOGE Co-Lead Elon Musk Believes &#8216;All Energy Generation Will Be Solar&#8217; — Here&#8217;s What UBS Recommends After Election Dip</a>
Image via Wikimedia Commons

Government

Macro Economic Events

Macro Notification

Regulations

Entrepreneurship

Politics

Economics

Donald Trump's DOGE Initiative To Have 'Marginal Impact' Says Analyst As Elon Musk Aims To Target Over $500B In Federal Expenditures

Meritage also announced that its Board of Directors has approved a $250 million increase to the Company's share repurchase authorization. This increase combined with $15 million in systematic buybacks on a quarter to date basis brings the Company's total authorized share repurchase program to $334 million as of November 21, 2024.

Reported Earlier, Meritage Homes Declares $0.75 Dividend And Expands Share Buyback By $250M

Total Revenue was ¥18.9 billion for the fiscal year ended June 30, 2024, from ¥17.4 billion for the fiscal year ended June 30, 2023.
The major revenue component, Real Estate Sales, increased to ¥18.5 billion from ¥17.1 billion, 8.1% year over year, in the fiscal year ended June 30, 2024.

Earnings

Reported Earlier, Lead Real Estate Reported FY24 EPS ¥46.93 Down From ¥48.96 YoY, Revenue ¥18.9B Up From ¥17.4B YoY

The gross proceeds of the offering are expected to be $12.1 million, excluding the exercise of the underwriter's option, if any, of approximately $1.8 million, and excluding underwriting discounts and commissions and other offering-related expenses. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital.

KSCP

Reported Earlier, Knightscope Prices $12.1M Public Offering Of 1.21M Class A Common Stock At $10/Share

Econ #s

Germany Gross Domestic Product (YoY) For Q3 -0.3% Vs. -0.2% Est.; -0.2% Prior

Germany Gross Domestic Product (QoQ) For Q3 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Retail Sales (MoM) For October -0.7% Vs. -0.3% Est.; 0.1% (Revised) Prior

U.K. Retail Sales (YoY) For October 2.4% Vs. 3.4% Est.; 3.2% (Revised) Prior

U.K. Core Retail Sales (YoY) For October 2.0% Vs. 3.3% Est.; 3.2% (Revised) Prior

U.K. Core Retail Sales (MoM) For October -0.9% Vs. -0.3% Est.; 0.1% (Revised) Prior

The Securities and Exchange Commission&#8217;s (SEC) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">lawsuits against cryptocurrency companies</a> will likely reach settlements once Chair Gary Gensler steps down in January 2025, according to crypto asset manager Pantera&#8216;s chief legal officer Katrina Paglia.
What Happened: Speaking at the North American Blockchain Summit in Dallas on Thursday, Paglia <a href="https://cointelegraph.com/news/sec-lawsuits-quietly-go-away-after-gensler-steps-down-pantera-clo">said</a>, according to Cointelegraph that while the SEC won&#8217;t completely withdraw its claims, many cases will &#8220;quietly go away&#8221; with defendants paying settlements under &#8220;neither admit nor deny&#8221; terms.
&#8220;The regulator will get to make some level of a statement and get something for the value of time and energy spent,&#8221; Paglia said, noting this would be &#8220;very beneficial&#8221; for resolving the extensive litigation.
The comments come as President-elect Donald Trump&#8216;s transition team actively shapes what appears to be a dramatically different approach to crypto regulation. 
See Also: <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K: That&#8217;s The Moment Altcoins &#8216;Shoot Off&#8217;</a>
Why It Matters: The incoming administration is reportedly vetting candidates for the first-ever White House <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">cryptocurrency policy role</a> while major industry players like Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong engage in <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42114875/coinbase-ceo-brian-armstrong-stands-out-as-candidate-for-donald-trumps-reported-crypto-czar-position-cardano-co-founder-says">high-level discussions</a>.
Industry experts see the potential for <a href="https://www.benzinga.com/24/11/42069770/us-congress-could-set-the-stage-for-broader-crypto-adoption-says-digital-asset-leader">significant policy shifts</a>, with Hunting Hill Global Capital&#8216;s CIO Adam Guren emphasizing the need for &#8220;thoughtful policy&#8221; and clear definitions for digital assets. &#8220;Well-defined classifications would encourage engagement from both individual and institutional investors,&#8221; Guren noted.
The market has responded positively to these developments, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">approaching $100,000</a> amid reports that companies including Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Kraken, and Circle (CRYPTO: USD) are seeking representation on <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">Trump&#8217;s promised crypto advisory council</a>.
The SEC under Gensler&#8217;s leadership has pursued actions against numerous high-profile crypto companies, including Ripple, Binance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), Kraken, and others, in what many in the industry have characterized as an aggressive regulatory approach.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin&#8217;s Path To $100K &#8216;Inevitable&#8217; But Crypto Community Is &#8216;Leveraged To The Gills,&#8217; Warns Galaxy&#8217;s Mike Novogratz, Predicts Correction To $80K Ahead</a></li>
</ul>
SEC Gary Gensler. Photo by Third Way Think Tank on Flickr
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$XRP

COIN

As Gary Gensler Eyes 2025 Exit, SEC Crypto Cases Could 'Quietly Disappear' Under Trump's Pro-Bitcoin Agenda, Says Pantera Capital's Katrina Paglia

The Company intends to use net proceeds from the offering for general corporate purposes, which may include new debt and equity investment opportunities and the repayment of a portion of its outstanding indebtedness.

Reported Earlier, SL Green Realty Prices 5,063,291 Common Shares At $79/Share

The billionaire Republican megadonor and Citadel CEO Ken Griffin has expressed openness to selling a minority stake in the $65 billion hedge fund he established in 1990.
What Happened: Griffin has previously sold stakes in his ventures. Two years ago, Sequoia Capital acquired a stake in Citadel Securities for $1.15 billion, valuing the market maker at $22 billion. Recently, Citadel Securities received a $5 billion investment offer from a private equity firm, which Griffin mentioned would help the company remain private longer.
In an <a href="https://www.bloomberg.com/news/articles/2024-11-21/ken-griffin-says-he-s-open-to-selling-minority-stake-in-citadel">interview</a> with&nbsp;Bloomberg on Thursday at the Economic&nbsp;Club of New York, Griffin stated,&nbsp;"We would be open to&nbsp;the possibility of selling a&nbsp;minority stake in Citadel at&nbsp;some point in the future."
Griffin highlighted the challenges of public capital markets, stating,&nbsp;"We need to make being&nbsp;public in the United States&nbsp;a much more attractive proposition."&nbsp;
Despite the offer, Griffin did not confirm acceptance and ruled out taking Citadel Securities public soon. When considering potential partners, Griffin seeks firms similar to Sequoia that can enhance Citadel&#8217;s business operations.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42102652/michael-saylors-microstrategy-takes-wall-street-by-storm-becomes-second-most-traded-stock-after-nvidia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michael Saylor&#8217;s MicroStrategy Takes Wall Street By Storm, Becomes Second-Most Traded Stock After Nvidia</a>
Why It Matters:&nbsp;Griffin, a prominent figure in the financial world, has built&nbsp;Citadel&nbsp;into a powerhouse with over $65 billion in assets. As a mega-donor to the Republican Party, he recently voiced concerns over&nbsp;<a href="https://www.benzinga.com/news/global/24/11/42056528/gop-megadonor-ken-griffin-warns-of-slippery-slope-in-trumps-tariff-policies-sees-us-returning-to-the-business-of-business">Donald Trump&#8216;s tariff policies</a>, warning they could hinder U.S. competitiveness. 
In the past year, Citadel has achieved remarkable financial success, <a href="https://www.benzinga.com/general/23/12/36365068/show-me-the-money-inside-ken-griffins-citadels-jaw-dropping-7-billion-return">returning $7 billion to clients </a>after a 30% profit surge. Citadel&#8217;s multistrategy fund, Wellington, has gained nearly 15% year-to-date, making it one of the top-performing hedge funds. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42102769/floki-beats-dogecoin-shiba-inu-with-double-digit-gains-after-coinbase-listing-announcement?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Floki Beats Dogecoin, Shiba Inu With Double-Digit Gains After Coinbase Listing Announcement</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Dan G via Flickr

GOP Megadonor Ken Griffin Is 'Open To The Possibility' Of Selling Minority Stake In Citadel

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index moved to the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jomes index gaining more than 450 points during the session.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose by 0.5% on Thursday after the company posted upbeat earnings and sales results. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell 2.2% on Thursday following a report suggesting the company is likely to be investigated under the EU&#8217;s Digital Markets Act next year.
Shares of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) plunged around 4.7% following the U.S. Department of Justice&#8217;s (DOJ) announcement of sweeping remedies in its high-profile antitrust lawsuit against Google.
On the economic data front, U.S. existing home sales gained by 3.5% from the previous month to an annualized rate of 3.96 million in October. The Philadelphia Fed Manufacturing Index fell to -5.5 in November from 10.3 in the previous month, and compared to market estimates of 8. U.S. initial jobless claims declined by 6,000 from the previous week to 213,000 in the week ending Nov. 16.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, financials, and consumer staples stocks recording the biggest gains on Thursday. However, consumer discretionary and communication services stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 462 points to 43,870.35 on Thursday. The S&amp;P 500 rose 0.53% to 5,948.71, while the Nasdaq Composite rose 0.03% at 18,972.42 during Thursday's session.
Investors are awaiting earnings results from Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) and Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 57.4, the index moved to the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 49.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Long Ideas

Pre-Market Outlook

Trading Ideas

AMZN

DXLG

GOOG

GOOGL

NVDA

Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To 'Greed' Zone

The gross proceeds to the Company from the offering are expected to be approximately $8.2 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures. The offering is expected to close on or about November 25, 2024, subject to the satisfaction of customary closing conditions.

MODD

Reported Earlier, Modular Medical Prices $8.2M Public Offering Of 5,450,573 Common Shares At $1.50/Share

The Company intends to use the net proceeds from the Offering for general corporate purposes, including funding future investments, making capital expenditures and funding working capital. The Company has granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes. The Notes will be issued in minimum denominations of $25.00 and integral multiples of $25.00 in excess thereof. The Offering is expected to close on November 27, 2024.

METC

Reported Earlier, Ramaco Resources Prices $50M Senior Unsecured Notes Offering At 8.375% Interest Due 2029

Press Releases

Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments

Financing & Partnership News Send Shares of this Stem-Cell Therapy Company on a Tear

TSX:HEM

Hemostemix

Photo by Chris Montgomery on <a href="https://unsplash.com/photos/smgTvepind4">Unsplash</a>

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

This year&rsquo;s <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Sciences Investor Forum</a>, running from 9:30 a.m. to 3:30 p.m. Dec. 16, introduces 12 publicly listed life science companies aiming to improve the quality of human life.

From biopharmaceuticals and epigenetics to psychedelics and metabolic health, each company has chosen a niche through which to achieve this goal. Attendees, investors and stakeholders will watch and listen as each of these companies explains their latest ideas, prompting watchers to wonder: What new scientific development will change human life as we know it?

For ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>), the answer to this question may reportedly lie in its Food and Drug Administration (FDA)-approved Lap-Band&reg; Program, which provides a minimally invasive, long-term treatment for obesity. Meanwhile, VolitionRx Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#NYSE">VNRX</a>) will argue that its Nucleosomics&trade; platform will radically improve patients&rsquo; ability to catch and monitor life-changing diseases early. Mind Cure Health Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MCURF#OTCQX">MCURF</a>) will posit that its research on the effect of digital therapeutics and psychedelic compounds on mental health will challenge our understanding of conventional mental health therapy. Nine more companies will post their arguments, but investors will only get to hear the full story at the forum.

The <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Science Investor Forum</a> may present a window of opportunity for investors and traders, allowing them to hear exclusively from companies attempting to be health leaders of the future. The 1-day marathon event is free for everyone and requires only a simple email sign-up to join.&nbsp;

<h2>Life Sciences Investor Forum Agenda</h2>

A complete list of the agenda is available on the <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Science Investor Forum</a>&rsquo;s main page.

Time: 9:30 a.m. EST&nbsp;

Company: <a href="https://www.redhillbio.com/investors/overview/default.aspx">RedHill BioPharma Ltd.</a>&nbsp;

Ticker: (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; gastrointestinal and infectious diseases

Speaker information: Guy Goldberg, Chief Business Officer

Time: 10 a.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/RSPI/overview">RespireRx Pharmaceuticals Inc.</a>&nbsp;

Ticker: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/RSPI#OTCQB">RSPI</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; psychiatric and neurological disorders

Speaker information: Jeff Margolis, SVP, Treasurer, CFO and Member of Board of Directors

Time: 10:30 a.m. EST&nbsp;

Company:<a href="https://www.otcmarkets.com/stock/RLFTF/overview"> Relief Therapeutics Holding </a>SA

Ticker: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/RLFTF#OTCQB">RLFTF</a>)

Industry: Biopharmaceuticals &mdash; respiratory and rare and specialty

Speaker information: Jack Weinstein, chief financial officer and treasurer

Time: 11 a.m. EST&nbsp;

Company: <a href="https://ir.volition.com/">VolitionRx Limited</a>

Ticker: (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#NYSE">VNRX</a>)&nbsp;

Industry: Epigenetics &mdash; cancer screening and veterinary&nbsp;

Speaker information: Scott Powell, head of investor relations and U.S. chief financial officer

Time: 11:30 a.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/MCURF/overview">Mind Cure Health Inc.</a>

Ticker: (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MCURF#OTCQX">MCURF</a>)&nbsp;

Industry: Pharmaceuticals &mdash;&nbsp; psychedelics and mental health

Speaker Information: Kelsey Ramsden, president and CEO

Time: 12 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/ACOGF/overview">Alpha Cognition</a>, Inc.

Tickers: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/ACOGF#OTCQB">ACOGF</a>), (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#TSXV">ACOG</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; Alzheimer&rsquo;s disease and amyotrophic lateral sclerosis (ALS)

Speaker information: Michael McFadden, CEO

Time: 12:30 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/EMMA/overview">Emmaus Life Sciences Inc.</a>

Ticker: (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/EMMA#OTCQX">EMMA</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; rare and orphan diseases&nbsp;

Speaker information: Yutaka Niihara, CEO and chairman

Time: 1 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/HMTXF/overview">Hemostemix Inc.</a>&nbsp;

Tickers: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/HMTXF#OTCQB">HMTXF</a>), (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/HEM#TSXV">HEM</a>)&nbsp;

Industry: Biotechnology &mdash; stem cell therapies

Speaker information: Thomas Smeenk, co-founder, president and CEO

Time: 1:30 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/JNHMF/overview">Jack Nathan Medical Corp</a>.

Tickers: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/JNHMF#OTCQB">JNHMF</a>), (TSX:-V JNH)&nbsp;

Industry: Primary-care medical clinics

Speaker information: Glenn Copeland, CEO and chief medical officer,&nbsp; David Berman, chief financial officer

Time: 2 p.m. EST&nbsp;

Company: <a href="https://ir.reshapelifesciences.com/">ReShape Lifesciences Inc.</a>

Ticker: (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>)&nbsp;

Industry: Weight loss and metabolic health

Speaker information: Bart Bandy, CEO and president, Tom Stankovich, CFO

Time: 2:30&nbsp; p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/BABYF/profile">Else Nutrition Holdings Inc.</a>

Ticker: (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/BABYF#OTCQX">BABYF</a>), (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/BABY#TSXV">BABY</a>)&nbsp;

Industry: Plant-based nutrition

Speaker information: Hamutal Yitzhak, founder and CEO

Time: 3 p.m. EST&nbsp;

Company: <a href="http://investors.salariuspharma.com/">Salarius Pharmaceuticals, Inc.</a>

Ticker: (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)&nbsp;

Industry: Biotechnology - Cancer

Speaker information: David Arthur, CEO

A complete list of the agenda is available on the <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Science Investor Forum</a>&rsquo;s main page.&nbsp;

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Comments

Hemostemix

News

Latest news for Hemostemix (OTC:HMTXF) Stock

Tuesday, December 14, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga